0.41 0 (0%) | 01-16 19:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.57 | 1-year : | 0.71 |
Resists | First : | 0.49 | Second : | 0.61 |
Pivot price | 0.41 ![]() |
|||
Supports | First : | 0.31 | Second : | 0.25 |
MAs | MA(5) : | 0.4 | MA(20) : | 0.44 ![]() |
MA(100) : | 0.47 ![]() |
MA(250) : | 0.6 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 61.5 ![]() |
D(3) : | 50.6 ![]() |
RSI | RSI(14): 36.2 | |||
52-week | High : | 1 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CWBR ] has closed above bottom band by 43.3%. Bollinger Bands are 60.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.41 - 0.41 | 0.41 - 0.41 |
Low: | 0.4 - 0.41 | 0.41 - 0.41 |
Close: | 0.41 - 0.41 | 0.41 - 0.41 |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Sat, 25 Jan 2025
Morphogenesis, Inc. announced that it expects to receive $15 million in funding from CohBar, Inc. - Marketscreener.com
Wed, 01 Nov 2023
Why CohBar (CWBR) Stock Is Down Nearly 50% Today - TradingView
Sun, 18 Jun 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SYNH, PDCE, GHL, CWBR - EIN News
Mon, 26 Sep 2022
7 Nasdaq Stocks to Sell Before They Die - InvestorPlace
Mon, 01 Nov 2021
5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes - Penny Stocks
Mon, 24 Aug 2020
CohBar Announces First Subjects Dosed in its Phase 1b - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 2 (M) |
Held by Insiders | 15 (%) |
Held by Institutions | 6.2 (%) |
Shares Short | 15 (K) |
Shares Short P.Month | 29 (K) |
EPS | -4.37 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.26 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -48.4 % |
Return on Equity (ttm) | -84 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -4.48 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -8 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.1 |
PEG Ratio | 0 |
Price to Book value | 0.12 |
Price to Sales | 0 |
Price to Cash Flow | -0.16 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |